What is frustrating the search for treatment of dementia? Fraud or ideas?

Abstract

The search for a treatment for dementia has been troubled by recent evidence of laboratory fraud. While acknowledging the seriousness of fraud, the author argues that the search for treatment has been slowed more by scientists' failure adequately to address two questions: 1) Why is dementia delayable before diagnosis yet unstoppable after diagnosis? And 2) How did molecular markers of dementia (like the peptide Aβ) evolve? What do they do for the individual, that made their evolution possible? These questions are addressed and their implications for the delay and treatment of dementia are discussed.